Rankings
▼
Calendar
SYRE Q4 2025 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
SYRE
Spyre Therapeutics, Inc.
$3B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$90M
Gross Profit
$45M
50.0% margin
Operating Income
-$57M
-63.2% margin
Net Income
-$63M
-69.1% margin
EPS (Diluted)
$-0.69
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$45M
Free Cash Flow
-$45M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$778M
Total Liabilities
$63M
Stockholders' Equity
$715M
Cash & Equivalents
$86M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$90M
$0
—
Gross Profit
$45M
$0
—
Operating Income
-$57M
-$61M
+6.7%
Net Income
-$63M
-$56M
-11.1%
← FY 2025
All Quarters